Results 71 to 80 of about 31,541 (206)
Медицинский вестник Юга России, 2018 Objective: to characterize the efcacy of nelfnavir and lopinavir/ritonavir in the starting regimens of antiretroviral therapy for HIV-infected pediatric patients.Materials and methods: 50 HIV-infected patients aged 24-36 months were treated with abacavir
V. B. Denisenko,, E. N. Simovanyan
doaj +1 more source
Pharmaceutical Sciences and Research, 2020 Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases.
Ana Khusnul Faizah +2 more
doaj +1 more source
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review [PDF]
, 2020 OBJECTIVE: Lopinavir/ritonavir has been used for the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus infections.
Servillo G., Vargas M., Einav S.
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 193-202, July 2026.Although patients with acute coronary syndrome supported by veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR ...
Soyoung Kang +9 more
wiley +1 more source
NanomaterialsLopinavir (LPV) and ritonavir (RTV) are two of the essential antiretroviral active pharmaceutical ingredients (APIs) characterized by poor solubility. Hence, attempts have been made to improve both their solubility and dissolution rate.
Ewelina Łyszczarz +5 more
doaj +1 more source
Drug Delivery, 2017 Topical and transdermal drug delivery has great potential in non-invasive and non-oral administration of poorly bioavailable therapeutic agents. However, due to the barrier function of the stratum corneum, the drugs that can be clinically feasible ...
Ki-Taek Kim +10 more
doaj +1 more source
In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors [PDF]
, 2002 The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other protease inhibitors over a range of two-drug combination ratios was evaluated.
Dale J. Kempf +6 more
core +1 more source
Health Economics, Volume 35, Issue 7, Page 1118-1130, July 2026.ABSTRACT Syphilis, a sexually transmitted infection that can lead to serious health complications, was almost eliminated in the United States by 2000. But since then, its incidence began to increase, recently reaching a 60‐year peak. We suggest that the introduction of the highly active antiretroviral therapy (HAART) drug regimen, which transformed HIV
David Beheshti +2 more
wiley +1 more source
HIV Medicine, Volume 27, Issue 7, Page 1132-1143, July 2026.Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson +13 more
wiley +1 more source
Lopinavir: the old champion [PDF]
, 2011 Lopinavir/ritonavir approval for use in antiretroviral treatment 10 years ago was very important for the recognition of boosted protease inhibitor (PI)-based therapy as an attractive option for first-line therapy.
Estevão Portela Nunes +5 more
core +1 more source